PT Kalbe Farma Tbk (KLBF) Q1 2026 earnings summary

Executive summary

• Net sales for Q1 2026 reached Rp9,678.4 billion, up 10.1% year-over-year from Rp8,788.2 billion in Q1 2025.

• Net income attributable to owners was Rp1,028.9 billion, a 4.4% decrease from Rp1,076.8 billion in Q1 2025.

• Total assets grew to Rp31,985.2 billion as of March 31, 2026, compared to Rp30,699.3 billion at year-end 2025.

Financial highlights

• Gross profit increased to Rp3,706.9 billion from Rp3,619.1 billion year-over-year.

• Operating income before tax was Rp1,351.9 billion, down from Rp1,429.3 billion in Q1 2025.

• Basic EPS was Rp22.74, compared to Rp23.57 in Q1 2025.

• Cash and cash equivalents at period end were Rp4,392.7 billion, up from Rp4,331.4 billion at year-end 2025.

• Total equity increased to Rp25,734.7 billion from Rp24,728.5 billion at year-end 2025.

Outlook and guidance

• Management continues to monitor geopolitical risks and macroeconomic volatility, especially related to Myanmar and the Middle East.

• No direct operations in conflict zones, but indirect impacts on supply chain, FX, and demand are being assessed.